Pure red cell aplasia associated with concomitant use of mycophenolate mofetil and ribavirin in post-transplant recurrent hepatitis C
- 1 February 2006
- journal article
- Published by Frontiers Media SA in Transplant International
- Vol. 19 (2) , 170-171
- https://doi.org/10.1111/j.1432-2277.2005.00242.x
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis CTransplant International, 2004
- Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunctionTransplant International, 2004
- Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantationTransplant International, 2004
- Ribavirin-Induced Pure Red-Cell Aplasia during Treatment of Chronic Hepatitis CNew England Journal of Medicine, 2004
- Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patientsClinical Nephrology, 2003
- Interferon-ɑ-induced pure red cell aplasia following chronic myelogenous leukemiaAnti-Cancer Drugs, 2001
- Pure red cell aplasiaBritish Journal of Haematology, 2000
- Reproducible erythroid aplasia caused by mycophenolate mofetilPediatric Nephrology, 2000
- RED CELL APLASIA IN CHILDREN ON TACROLIMUS AFTER LIVER TRANSPLANTATIONTransplantation, 1998
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995